当前位置:
X-MOL 学术
›
J. Crohns Colitis
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Influence of Drug Exposure on Vedolizumab-Induced Endoscopic Remission in Anti-Tumour Necrosis Factor [TNF] Naïve and Anti-TNF Exposed IBD Patients
Journal of Crohn's and Colitis ( IF 8 ) Pub Date : 2019-08-29 , DOI: 10.1093/ecco-jcc/jjz151 Bram Verstockt 1, 2 , Evelien Mertens 1 , Erwin Dreesen 3 , An Outtier 1 , Maja Noman 1 , Sophie Tops 3 , Ganel Schops 1 , Gert Van Assche 1, 2 , Séverine Vermeire 1, 2 , Ann Gils 3 , Marc Ferrante 1, 2
Journal of Crohn's and Colitis ( IF 8 ) Pub Date : 2019-08-29 , DOI: 10.1093/ecco-jcc/jjz151 Bram Verstockt 1, 2 , Evelien Mertens 1 , Erwin Dreesen 3 , An Outtier 1 , Maja Noman 1 , Sophie Tops 3 , Ganel Schops 1 , Gert Van Assche 1, 2 , Séverine Vermeire 1, 2 , Ann Gils 3 , Marc Ferrante 1, 2
Affiliation
Vedolizumab has demonstrated efficacy and safety in patients with Crohn's disease [CD] and ulcerative colitis [UC]. Endoscopic outcome data are limited, especially in anti-tumour necrosis factor [TNF] naïve patients. The present study compared endoscopic outcome in anti-TNF naïve and exposed patients, and explored if this was affected by drug exposure.
中文翻译:
药物暴露对维多珠单抗诱导的抗肿瘤坏死因子[TNF]幼稚和抗TNF暴露的IBD患者内镜缓解的影响
Vedolizumab已证明对克罗恩病[CD]和溃疡性结肠炎[UC]患者具有疗效和安全性。内窥镜检查结果数据有限,尤其是在抗肿瘤坏死因子[TNF]初治患者中。本研究比较了初次接触和未接受过抗TNF治疗的患者的内镜转归,并探讨了这是否受到药物暴露的影响。
更新日期:2020-04-17
中文翻译:
药物暴露对维多珠单抗诱导的抗肿瘤坏死因子[TNF]幼稚和抗TNF暴露的IBD患者内镜缓解的影响
Vedolizumab已证明对克罗恩病[CD]和溃疡性结肠炎[UC]患者具有疗效和安全性。内窥镜检查结果数据有限,尤其是在抗肿瘤坏死因子[TNF]初治患者中。本研究比较了初次接触和未接受过抗TNF治疗的患者的内镜转归,并探讨了这是否受到药物暴露的影响。